Seventeen thousand seven hundred and thirty one H. pylori strains were collected from eight selleck inhibitor areas of two provinces in coastal southeast China from 2010 to

2012. The resistance of these strains to six antibiotics was tested using the agar dilution method. The resistance rates to clarithromycin, metronidazole, levofloxacin, amoxicillin, gentamicin and furazolidone were 21.5, 95.4, 20.6, 0.1, 0.1 and 0.1%, respectively. Double, triple and quadruple antibacterial resistant percentages were 25.5, 7.5 and 0.1%, respectively. A positive association between the resistance to levofloxacin and to clarithromycin was found, but there was a negative correlation in the resistances to levofloxacin and to metronidazole. The prevalence of H. pylori resistance to clarithromycin, metronidazole, levofloxacin and multiple antibiotics

in coastal southeast China is high. Choice of therapy should be individualized based on a susceptibility test in this region of the country. “
“To document the efficacy and tolerability of 14-day bismuth–lansoprazole–amoxicillin–clarithromycin (BLAC) regimen for Helicobacter pylori (H. pylori) eradication as a first-line therapy. Patients were considered eligible for the study if they underwent upper gastrointestinal endoscopy, and H. pylori infection was diagnosed through histologic examination of antral and body biopsy samples. Primary end point of this study was to evaluate the eradication rate of 14-day BLAC regimen therapies. H. pylori

eradication was assessed using the 13C urea breath test selleck chemical performed 6 weeks after the completion of treatment. All patients were asked to fill in a validated questionnaire to report therapy-related side effects. Each symptom was graded from absent or present. 上海皓元 Ninety-seven (21 men and 76 women) were enrolled. All the patients completed the study. The H. pylori eradication rate was 90.7% (88 of 97 patients). Side effects were observed in reasonable percentages, and none of the patients left the study because of drug side effect. Bismuth–lansoprazole–amoxicillin–clarithromycin regimen as a 2-week course achieved an acceptable eradication rate with relatively mild side effects. “
“This article reviews the literature published pertaining to Helicobacter pylori eradication over the last year. The general perception among clinicians and academics engaged in research on H. pylori has been that eradication rates for first-line therapies are falling, although some data published this year have cast doubt on this. The studies published this year have therefore focussed on developing alternative strategies for the first-line eradication of H. pylori. In this regard, clear evidence now exists that both levofloxacin and bismuth are viable options for first-line therapy. The sequential and “concomitant” regimes have also been studied in new settings and may have a role in future algorithms also.